THERAGNOSTIC PRODUCT REGULATION IN RUSSIA

1. INTRODUCTION

Theragnostic products combine therapeutic and diagnostic functions within an integrated medical approach. These products enable healthcare professionals to identify particular biological targets, select suitable treatments, monitor therapeutic responses, and evaluate treatment effectiveness. They are particularly important in oncology, molecular medicine, nuclear medicine, personalized healthcare, and precision biotechnology.

Examples include radiopharmaceutical products used for diagnostic imaging and targeted treatment, companion diagnostic tests associated with targeted cancer medicines, and molecular platforms that identify biomarkers to guide therapeutic decisions.

In Russia, theragnostic products are regulated through a combination of pharmaceutical legislation, medical device regulation, clinical investigation requirements, radiation safety legislation, healthcare standards, and personal data protection rules.

The principal regulatory objective is to ensure that diagnostic accuracy, therapeutic effectiveness, manufacturing quality, patient safety, and clinical reliability are maintained throughout the product lifecycle.

2. LEGAL AND REGULATORY FRAMEWORK

A. FEDERAL LAW NO. 61-FZ OF 12 APRIL 2010 ON CIRCULATION OF MEDICINES

This legislation establishes the principal framework for the registration, manufacture, quality control, distribution, and pharmacovigilance of medicinal products in Russia.

Its relevance includes:

State registration of therapeutic medicinal products.

Requirements for pharmaceutical manufacturing quality.

Clinical and preclinical evaluation.

Quality and safety documentation.

Monitoring of adverse drug reactions.

Post-registration regulatory supervision.

Theragnostic medicinal products containing therapeutic pharmaceutical substances or radiopharmaceutical components may fall within this framework.

B. FEDERAL LAW NO. 323-FZ OF 21 NOVEMBER 2011 ON THE FUNDAMENTALS OF HEALTH PROTECTION OF CITIZENS

This legislation establishes general principles governing medical care, patient rights, medical interventions, informed consent, and healthcare safety.

It is particularly relevant when theragnostic products are used for diagnosis and treatment within Russian healthcare institutions.

C. FEDERAL LAW NO. 38-FZ OF 30 MARCH 1999 ON RADIOLOGICAL SAFETY OF THE POPULATION

This legislation establishes legal requirements for protecting individuals against harmful radiation exposure.

It is relevant to theragnostic products involving radioactive diagnostic and therapeutic substances, including radiopharmaceutical applications.

D. FEDERAL LAW NO. 3-FZ OF 9 JANUARY 1996 ON RADIATION SAFETY OF THE POPULATION

This legislation establishes radiation protection principles, including requirements concerning exposure, safety, and protection of patients and personnel.

E. EURASIAN ECONOMIC UNION REGULATORY FRAMEWORK

Russia participates in the Eurasian Economic Union (EAEU), whose pharmaceutical and medical device regulations establish harmonized requirements for relevant products.

Important instruments include:

EAEU Council Decision No. 78 of 3 November 2016 concerning medicinal product registration and examination.

EAEU Council Decision No. 46 of 12 February 2016 concerning medical device registration and examination.

Applicable EAEU Good Manufacturing Practice requirements.

The correct regulatory route depends on whether a theragnostic component is classified as a medicinal product, medical device, or another regulated product.

3. CLASSIFICATION OF THERAGNOSTIC PRODUCTS

A. RADIOPHARMACEUTICAL THERAGNOSTIC PRODUCTS

These products combine diagnostic imaging and targeted radionuclide therapy. Their regulation involves medicinal product registration, radiation protection, manufacturing quality, and clinical safety.

B. COMPANION DIAGNOSTIC PRODUCTS

These are diagnostic tests used to identify biomarkers that indicate whether a patient is likely to benefit from a particular therapeutic medicine.

They may include molecular assays, immunohistochemistry tests, and genetic testing platforms.

C. MOLECULAR THERAGNOSTIC PLATFORMS

These products combine biomarker detection with therapeutic decision-making. Their regulatory classification depends on their intended medical purpose and technological characteristics.

D. PERSONALIZED ONCOLOGY PRODUCTS

These products support individualized cancer treatment by identifying molecular targets and selecting suitable targeted therapies.

E. INTEGRATED DIAGNOSTIC-THERAPEUTIC SYSTEMS

These systems may contain several components, including diagnostic instruments, reagents, software, and therapeutic products. Each component may require separate regulatory assessment.

4. PRODUCT REGISTRATION AND APPROVAL REQUIREMENTS

Theragnostic products must undergo the appropriate registration procedures before lawful commercialization in Russia.

The main requirements include:

Identification of the product's intended medical purpose.

Determination of its medicinal product or medical device classification.

Submission of quality and manufacturing information.

Evaluation of analytical performance for diagnostic components.

Evaluation of therapeutic safety and effectiveness.

Submission of relevant preclinical and clinical evidence.

Assessment of product stability and storage conditions.

Verification of manufacturing quality standards.

Review of labeling and patient information.

Compliance with applicable pharmacovigilance and post-market requirements.

The Ministry of Health of the Russian Federation and the Federal Service for Surveillance in Healthcare (Roszdravnadzor) perform important regulatory functions within their respective areas of responsibility.

5. CLINICAL TRIAL AND VALIDATION REQUIREMENTS

Clinical evaluation is essential because theragnostic products influence both diagnostic decisions and therapeutic outcomes.

A. DIAGNOSTIC VALIDATION

Diagnostic components should demonstrate appropriate analytical and clinical performance.

Relevant considerations include:

Analytical sensitivity.

Analytical specificity.

Reproducibility.

Accuracy of biomarker identification.

Clinical validity.

Reliability of diagnostic interpretation.

B. THERAPEUTIC VALIDATION

Therapeutic components must demonstrate appropriate safety and effectiveness through the applicable clinical development and registration pathway.

C. INTEGRATED CLINICAL EVALUATION

Where a diagnostic test determines eligibility for a particular therapy, the relationship between the diagnostic result and the expected therapeutic outcome should be adequately supported by clinical evidence.

D. ETHICAL REVIEW

Clinical investigations involving human participants must comply with applicable ethical review, informed consent, and patient protection requirements.

6. MANUFACTURING AND QUALITY CONTROL

Manufacturing quality is particularly important because theragnostic products may involve pharmaceutical substances, biological materials, radioactive components, and diagnostic reagents.

Manufacturers must establish suitable quality management systems covering:

Raw material qualification.

Manufacturing process validation.

Product identity and purity.

Batch consistency.

Stability and shelf-life assessment.

Contamination control.

Packaging and labeling.

Storage and transportation.

Traceability and batch documentation.

Adverse event reporting procedures.

Radiopharmaceutical products require additional controls concerning radiation protection, radioactive material handling, and applicable nuclear and radiation safety requirements.

7. RADIOLOGICAL SAFETY AND PATIENT PROTECTION

Theragnostic products involving radioactive substances require special attention to patient and occupational radiation protection.

Russian radiation safety legislation establishes obligations concerning safe handling, exposure control, and protection of the population.

Healthcare institutions should ensure:

Appropriate authorization for regulated activities.

Qualified medical and technical personnel.

Radiation protection procedures.

Patient information and informed consent.

Appropriate monitoring of radiation exposure.

Safe radioactive material storage and disposal.

Incident reporting and corrective action.

The applicable requirements depend on the radioactive substance, activity, medical application, and facility authorization.

8. DATA PROTECTION AND PATIENT RIGHTS

Theragnostic products frequently process sensitive medical information, including genetic data, molecular biomarkers, pathology results, and treatment histories.

Relevant Russian legislation includes:

A. FEDERAL LAW NO. 152-FZ ON PERSONAL DATA

This law regulates the processing, storage, protection, and transfer of personal data.

B. FEDERAL LAW NO. 323-FZ

This law protects patient rights, including medical confidentiality and informed consent.

C. FEDERAL LAW NO. 149-FZ ON INFORMATION, INFORMATION TECHNOLOGIES AND INFORMATION PROTECTION

This legislation establishes broader requirements for information protection and information systems.

Healthcare organizations and manufacturers must ensure lawful data processing, appropriate confidentiality safeguards, and compliance with applicable cross-border data transfer restrictions.

9. POST-MARKET SURVEILLANCE AND PHARMACOVIGILANCE

Regulatory obligations continue after commercialization.

Manufacturers and relevant healthcare organizations must maintain appropriate systems for identifying, documenting, and reporting safety problems.

Important post-market considerations include:

Adverse drug reaction reporting.

Diagnostic performance monitoring.

Identification of false-positive and false-negative results.

Monitoring of therapeutic complications.

Product quality complaint investigations.

Corrective and preventive actions.

Recall and safety communication procedures.

Regulatory notification of significant safety concerns.

A diagnostic failure that results in inappropriate therapeutic selection may create additional professional, product, and institutional liability.

10. RELEVANT CASE LAWS AND JUDICIAL AUTHORITIES

Theragnostic regulation is a relatively specialized area, and there is no established body of Russian Supreme Court decisions specifically addressing integrated theragnostic products. The following authorities provide relevant legal principles concerning pharmaceutical regulation, medical liability, product safety, and patient rights.

1. Constitutional Court of the Russian Federation, Resolution No. 3-P of 28 February 2006

This decision concerns constitutional principles associated with citizens' rights to healthcare and access to medical assistance. Its broader principles are relevant when evaluating the state's responsibility to maintain lawful and accessible healthcare arrangements.

Authority: General constitutional healthcare authority; analogous application.

2. Constitutional Court of the Russian Federation, Resolution No. 2-P of 19 January 2016

This decision addresses constitutional questions concerning the legal regulation of pharmaceutical and medical activities. Its relevance to theragnostic regulation lies in the importance of balancing regulatory requirements, public interests, and legal certainty.

Authority: General regulatory-law authority; relevance should be assessed against the precise issue.

3. Donoghue v. Stevenson (1932)

The House of Lords established the modern negligence principle concerning the duty of manufacturers towards consumers. The principle is relevant by analogy where defective diagnostic reagents or therapeutic products cause patient injury.

Authority: Analogous product liability authority.

4. Bolam v. Friern Hospital Management Committee (1957)

The English court developed principles for assessing professional medical negligence by reference to responsible medical practice. This is relevant by analogy when evaluating professional decisions involving theragnostic test interpretation and treatment selection.

Authority: Analogous medical negligence authority.

5. Montgomery v. Lanarkshire Health Board (2015)

The UK Supreme Court emphasized the importance of disclosing material risks and reasonable treatment alternatives to patients. This principle is relevant by analogy to informed consent for complex diagnostic and therapeutic interventions.

Authority: Analogous patient-rights authority.

6. Sidaway v. Board of Governors of the Bethlem Royal Hospital (1985)

The House of Lords considered medical professionals' obligations concerning disclosure of treatment risks. The decision provides historical comparative context for informed consent and medical disclosure.

Authority: Analogous medical negligence authority.

7. Bolitho v. City and Hackney Health Authority (1997)

The House of Lords clarified that professional medical opinions relied upon in negligence disputes must withstand logical analysis. This is relevant by analogy when assessing the scientific and professional justification for theragnostic treatment decisions.

Authority: Analogous medical negligence authority.

11. REGULATORY CHALLENGES

Theragnostic product regulation in Russia faces several important challenges:

Determining the regulatory classification of integrated diagnostic and therapeutic products.

Coordinating medicinal product and medical device registration.

Establishing reliable clinical evidence for combined diagnostic and therapeutic applications.

Maintaining manufacturing consistency for complex products.

Ensuring radiation safety in nuclear medicine applications.

Protecting genetic and molecular patient information.

Managing false-positive and false-negative diagnostic results.

Establishing liability where diagnostic and therapeutic components fail together.

Ensuring compliance with EAEU regulatory requirements.

Maintaining effective post-market safety monitoring.

12. PRACTICAL COMPLIANCE REQUIREMENTS

Manufacturers, healthcare institutions, and biotechnology developers should adopt the following measures:

Determine the legal classification of every product component.

Identify the appropriate Russian or EAEU registration pathway.

Maintain complete clinical and analytical validation records.

Implement applicable GMP and quality management requirements.

Establish radiation protection arrangements where necessary.

Maintain patient consent and medical confidentiality procedures.

Establish pharmacovigilance and post-market surveillance systems.

Maintain product traceability and batch documentation.

Conduct periodic regulatory compliance audits.

Review changes in Russian pharmaceutical and EAEU legislation.

13. CONCLUSION

Theragnostic product regulation in Russia involves a multidisciplinary legal framework covering pharmaceutical registration, medical device regulation, clinical validation, radiation safety, manufacturing quality, patient rights, and personal data protection.

Federal Law No. 61-FZ, Federal Law No. 323-FZ, applicable radiation safety legislation, and EAEU regulatory instruments provide the principal legal foundations for the development and commercialization of theragnostic products.

The judicial principles associated with constitutional healthcare rights, manufacturer liability, medical negligence, scientific justification, and informed consent provide additional guidance for regulatory compliance and patient protection.

Ultimately, successful theragnostic product commercialization in Russia requires appropriate product classification, scientifically reliable diagnostic and therapeutic evidence, lawful registration, effective quality management, and continuous post-market monitoring. These requirements are essential to ensuring that integrated diagnostic and therapeutic technologies remain safe, effective, reliable, and legally compliant.